Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Preventive Cardiology
Are there any ongoing clinical trials related to endothelial dysfunction and accelerated or premature CAD that patients might be able to enroll in nationwide?
Related Questions
How soon after initiating oral anticoagulation therapy for atrial fibrillation can it be interrupted for surgery or procedures?
What are your top takeaways from ACC 2025?
Will TRYNGOLZA (olezarsen), recently approved for familial chylomicronemia syndrome, also lower triglycerides due to other genetic causes of hypertriglyceridemia?
What are your top takeaways from AHA 2024?
What is your approach to determining the safety, appropriateness, and timing of SPECT or PET MPI in patients admitted with NSTEMI and who remain chest pain-free and hemodynamically stable?
For a patient with known CAD and low baseline HDL, would a PCSK9 inhibitor be a better option than a statin, given concerns for paradoxical lowering of HDL levels with statin therapy that we can encounter in the outpatient clinical setting?
Does oral semaglutide provide similar cardiovascular risk reduction benefits as injectable semaglutide?
Is there any indication/benefit for heparin in a patient with suspected type 2 myocardial infarction?
What is the clinical significance of a paradoxical decrease in HDL cholesterol after starting statin therapy?
What would be your next diagnostic test of choice for a patient with findings concerning for silent ischemia on noninvasive functional testing in the absence of chest pain?
